tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Ciancio G et al. Current advantage of FK 506 in cadaveric kidney transplantation. 1996 Transplant. Proc. pmid:8623207
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Satomura K et al. Pharmacokinetics of FK 506 in living-related liver transplantation. 1996 Transplant. Proc. pmid:8623209
Loss M et al. Glucose and lipid metabolism in liver transplant patients under long-term tacrolimus (FK 506) monotherapy. 1996 Transplant. Proc. pmid:8623210
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Andrews WS et al. Comparison of cyclosporine- vs tacrolimus-based immunosuppression in pediatric liver transplantation. 1996 Transplant. Proc. pmid:8623452
Ketel BL et al. Tacrolimus-based vs cyclosporine-based immunotherapy in combined kidney-pancreas transplantation. 1996 Transplant. Proc. pmid:8623453
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Pirenne J et al. Bone marrow augmentation of kidney allografts can cause graft-versus-host disease in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623472
Ciancio G et al. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. 1996 Transplant. Proc. pmid:8623473
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Kawashima M et al. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. 1996 Lancet pmid:8898050
Drake M et al. The immunosuppressant FK506 ameliorates ischaemic damage in the rat brain. 1996 Acta Physiol. Scand. pmid:8899062
Zhang Q et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8799169
Spencer DM et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. 1996 Curr. Biol. pmid:8805308
Franke EK and Luban J Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. 1996 Virology pmid:8806510
Ichikawa Y et al. Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. 1996 Int. J. Urol. pmid:8776613
Mugiya S et al. Renal blood flow and serotonin metabolism in tacrolimus treated rats. 1996 Int. J. Urol. pmid:8776615
Dmitrewski J et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. 1996 J. Hepatol. pmid:8778189
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Cicalese L et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. 1996 Transplant. Proc. pmid:8907959
Reggiani P et al. Oral administration of FK 506 in a swine model of liver-small bowel allotransplantation. 1996 Transplant. Proc. pmid:8907965
Spada M et al. Bacterial translocation is enhanced in pig intestinal transplantation when the colon is included in the graft. 1996 Transplant. Proc. pmid:8907997
Alessiani M et al. Intestinal transplantation with and without the colon in FK 506 immunosuppressed pigs. 1996 Transplant. Proc. pmid:8908021
Asfar S et al. Small bowel transplantation. 1996 Transplant. Proc. pmid:8908039
Reyes J et al. Intestinal transplantation in children: five-year experience. 1996 Transplant. Proc. pmid:8908042
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Ho S et al. The mechanism of action of cyclosporin A and FK506. 1996 Clin. Immunol. Immunopathol. pmid:8811062
Nishino H et al. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. 1996 J. Chem. Neuroanat. pmid:8811425
Sonatore LM et al. The utility of FK506-binding protein as a fusion partner in scintillation proximity assays: application to SH2 domains. 1996 Anal. Biochem. pmid:8811923
Jonas S et al. Conversion to tacrolimus after liver transplantation. 1996 Transpl. Int. pmid:8748407
Guérette B et al. Increased interferon-gamma mRNA expression following alloincompatible myoblast transplantation is inhibited by FK506. 1996 Muscle Nerve pmid:8965835
Sharkey J et al. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. 1996 Stroke pmid:8969794
Hedayat S et al. Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. 1996 J Biopharm Stat pmid:8969977
Taler SJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. 1996 Transplantation pmid:8970613
Tanabe K et al. Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. 1996 Transplant. Proc. pmid:8658670
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Watanabe K et al. Immunosuppressive effect of bactobolamine in rat liver allotransplantation. 1996 Transplant. Proc. pmid:8658697
Tojimbara T et al. Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. 1996 Transplant. Proc. pmid:8658704
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
Freiberg RA et al. Specific triggering of the Fas signal transduction pathway in normal human keratinocytes. 1996 J. Biol. Chem. pmid:8940187
Poon M et al. Rapamycin inhibits vascular smooth muscle cell migration. 1996 J. Clin. Invest. pmid:8941644
Rokaw MD et al. Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells. 1996 J. Biol. Chem. pmid:8943313
Matsui A et al. Apparently increased trough levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation. 1996 Acta Paediatr Jpn pmid:9002314
Adachi M et al. Interleukin-2 (IL-2) upregulates BAG-1 gene expression through serine-rich region within IL-2 receptor beta c chain. 1996 Blood pmid:8943845
DeCenzo MT et al. FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes. 1996 Protein Eng. pmid:9005438
Przepiorka D et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. 1996 Blood pmid:8943876
Blecher O et al. A novel plant peptidyl-prolyl-cis-trans-isomerase (PPIase): cDNA cloning, structural analysis, enzymatic activity and expression. 1996 Plant Mol. Biol. pmid:8980498
McCall E et al. Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes. 1996 Circ. Res. pmid:8943949
Winkler M et al. Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation. 1996 Ther Drug Monit pmid:8946659
Nichterlein T et al. Effects of FK-506 on the course of murine salmonellosis. 1996 J Chemother pmid:8981186
Christophers E Psoriasis: mechanisms and entry points for possible therapeutic interventions. 1996 Australas. J. Dermatol. pmid:8713012
Alak AM and Lizak P Stability of FK506 in blood samples. 1996 Ther Drug Monit pmid:8721287
Yu C et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. 1996 Bone Marrow Transplant. pmid:8722370
Fealy MJ and Press BH Pinpointing the moment of allograft rejection. 1996 J Hand Surg Am pmid:8724501
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Jordan ML et al. The use of tacrolimus in renal transplantation. 1996 World J Urol pmid:8873438
Wada Y et al. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. 1996 Artif Organs pmid:8853794
Clark W Tacrolimus: immunosuppression following liver and kidney transplant. 1996 J Clin Pharm Ther pmid:8873845
Lochmüller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. 1996 Gene Ther. pmid:8854096
DiMartini AF et al. Prospective study of FK506 side effects: anxiety or akathisia? 1996 Biol. Psychiatry pmid:8874843
Horn F and Gross J A role for calcineurin in Dictyostelium discoideum development. 1996 Differentiation pmid:8855370
Lu YF et al. Calcineurin inhibitors, FK506 and cyclosporin A, suppress the NMDA receptor-mediated potentials and LTP, but not depotentiation in the rat hippocampus. 1996 Brain Res. pmid:8874888
Barkholt LM et al. Epstein-Barr virus DNA in serum after liver transplantation--surveillance of viral activity during treatment with different immunosuppressive agents. 1996 Transpl. Int. pmid:8875785
Shapiro R et al. Tacrolimus in pediatric renal transplantation. 1996 Transplantation pmid:8990356
Morris-Stiff G et al. Haemolytic uraemic syndrome associated with OKT3. 1996 Transpl. Int. pmid:8875800
Przepiorka D et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. 1996 Transplantation pmid:8990368
Kay JE Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. 1996 Biochem. J. pmid:8670043
Schmaldienst S and Horl WH Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. 1996 Nephrol. Dial. Transplant. pmid:8672015
Hartley AD et al. cAMP inhibits bud growth in a yeast strain compromised for Ca2+ influx into the Golgi. 1996 Mol. Gen. Genet. pmid:8709962
Tokime T et al. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. 1996 Neurosci. Lett. pmid:8710192
Dan Y et al. IL-3 augments TCR-mediated responses of type 2 CD4 T cells. 1996 J. Immunol. pmid:8598473
Soubrane O and Houssin D [Liver transplantation. Current aspects]. 1996 Presse Med pmid:8728904
Lampen A et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. 1996 Br. J. Pharmacol. pmid:8732283
Beretta L et al. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. 1996 EMBO J. pmid:8599949
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Morris RE Transplantation. Beware: shifting paradigms ahead. 1996 Dec 21-28 Lancet pmid:8973504
Shultz SL and Meriney DK Cyclosporine and tacrolimus: a comparison of immunosuppressants used for liver transplantation. 1996 Jul-Aug Dimens Crit Care Nurs pmid:8717641
Frezza EE et al. Small bowel transplantation: current progress and clinical application. 1996 Mar-Apr Hepatogastroenterology pmid:8714229
Seifeldin R et al. Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus. 1996 May-Jun Clin Ther pmid:8829025
Cumming DV et al. Pharmacological preconditioning of primary rat cardiac myocytes by FK506. 1996 Sep-Oct Basic Res. Cardiol. pmid:8922254
Soin AS and Jamieson NV Lessons learnt from the multicentre randomized trials of tacrolimus in liver transplantation. 1996 Sep-Oct Natl Med J India pmid:8937063
Kokudo N et al. Allogeneic hepatocyte and fetal liver transplantation and xenogeneic hepatocyte transplantation for Nagase's analbuminemic rats. 1996 Sep-Oct Cell Transplant pmid:8889223
Furukawa M et al. Analysis of PCR microchimerism induced by intrathymic inoculation of donor alloantigens in rats. 1996 Sep-Oct Cell Transplant pmid:8889237
de-la-Serna-Higuera C et al. Tacrolimus-induced bone marrow suppression. 1997 Lancet pmid:9291912
Fletcher L Specific neuroimmunophilin ligands to treat neurodegenerative disease. 1997 Mol Med Today pmid:9449119
Miwa S et al. Effect of anti-intercellular adhesion molecule-1 and anti-leukocyte function associated antigen-1 monoclonal antibodies on rat-to-mouse cardiac xenograft rejection. 1997 Surgery pmid:9186469
Arbustini E et al. Acute rejection and heart infection rates in FK 506- versus cyclosporine A-treated heart transplant recipients: an endomyocardial biopsy pathologic study. 1997 J. Heart Lung Transplant. pmid:9322152
Weil SJ et al. Chemotaxis of macrophages by a peritoneal fluid protein in women with endometriosis. 1997 Fertil. Steril. pmid:9130891
Xu M et al. Effect of peritransplant FTY720 alone or in combination with posttransplant FK 506 in a rat model of cardiac allotransplantation. 1997 Transplant. Proc. pmid:9365631
Filler G et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. 1997 Nephrol. Dial. Transplant. pmid:9269646
Azuma H et al. Atypical Epstein-Barr virus infection during and after intermittent FK506 therapy. 1997 Acta Paediatr Jpn pmid:9141259
Sabatini DM et al. Neural roles of immunophilins and their ligands. 1997 Mol. Neurobiol. pmid:9396011
Ballantyne CM et al. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. 1997 Curr. Opin. Cardiol. pmid:9192484
Noguchi N et al. Cyclic ADP-ribose binds to FK506-binding protein 12.6 to release Ca2+ from islet microsomes. 1997 J. Biol. Chem. pmid:9013543